Everything below concerns 白蛋白结合. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-21. Numbers and descriptions here follow the published literature rather than marketing material.
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
| Property | Value | Notes |
|---|---|---|
| 分子式 | C187H291N45O59 | 按主链与 C18 二酸侧链计算 |
| 分子量 | 约 4113.6 道尔顿 | 游离碱形式，随反离子略有差异 |
| 外观 | 白色至类白色冻干粉末 | 具吸湿性，需干燥保存 |
| 溶解性 | 微溶于水，易溶于碱性缓冲液 | 溶解性随 pH 升高而改善 |
| 等电点 | 约 5.4 | 影响缓冲液选择与聚集倾向 |
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
=== Biochemie === Da Proteine durch die meisten organischen Lösungsmittel denaturiert werden, setzt man bei der Proteinreinigung wässrige 2-Phasensysteme für die Extraktion ein. Das Prinzip beruht auf der Mischung zweier Lösungen, welche zwei getrennte Phasen ausbilden. Beispiele hierfür sind Wolkenpunktextraktionen oder Fällungen mit Polyethylenglykol- (PEG) oder Dextranlösungen. Die Wolkenpunktextraktion basiert auf der Phasentrennung einer einprozentigen (m/V) Triton-X114-Lösung oberhalb von 22 °C oder nach der Zugabe von Salzen und Natriumlaurylsulfat. Ebenso kommt eine Zweiphasenextraktion bei der DNA-Extraktion vor, in diesem Fall mit einer wässrigen und einer organischen Phase. Das Produkt löst sich entsprechend seinem Verteilungskoeffizienten unterschiedlich in den beiden Phasen.
=== Bodensanierung und Abwasserreinigung === Bei der Bodensanierung lassen sich Schadstoffe mit unterschiedlichen Lösemitteln aus kontaminierten Böden extrahieren. Hierzu hat sich auch die Hochdruckextraktion als geeignet herausgestellt, bei der man, ähnlich wie bei der Hochdruckextraktion von Kaffee, Hopfen oder Fetten und Ölen mit verdichteten Gasen, wie z. B. Kohlenstoffdioxid, extrahiert. Mithilfe von Phosphoreliminationsverfahren werden in Kläranlagen Phosphate aus Abwasser extrahiert, um sie als Phosphatdüngemittel wiedereinzusetzen.
Die Van-Deemter-Gleichung (Jan Jozef van Deemter, 1956) beschreibt mathematisch/physikalisch die Trennleistung in der Gas- und Flüssig-Chromatographie. Die Bodenhöhe H (HETP – Höhenäquivalent eines theoretischen Bodens, engl. height equivalent to a theoretical plate) wird durch folgende vereinfachte Formel beschrieben:
H: Bodenhöhe L: Länge der Säule N: Trennstufenzahl v: Geschwindigkeit der mobilen Phase A: Streudiffusion/Wirbeldiffusion (Eddy-Diffusion). Bei gepackten Säulen erhöht die Verwirbelung diesen Term. Er ist unabhängig von der Strömungsgeschwindigkeit. Bei Kapillarsäulen entfällt A. Es handelt sich um eine Streudiffusion, die durch unterschiedliche Flusswege einzelner Probemoleküle durch die Säule entsteht. Diese kommen durch wechselnde Form und Größe der Teilchen des Trägermaterials und ihre unregelmäßige Packung in der Säule zustande. Die Eddy-Diffusion ist besonders klein, wenn kleine Teilchen einheitlicher Größe homogen in der Säule gepackt sind. Term A ist außerdem vom Teilchendurchmesser der stationären Phase abhängig: A = 2 λ d (λ = Faktor, d = Teilchendurchmesser). B/v: Longitudinal-Diffusion, Diffusion in Längsrichtung der Säulenachse. Dieser Faktor ist abhängig von der Viskosität und Temperatur der mobilen Phase. Er ist abhängig vom Kehrwert der Strömungsgeschwindigkeit. Der Analyt diffundiert kontinuierlich vom konzentrierten Zentrum seiner Probezone weg. Term B ist von dem Diffusionskoeffizient der mobilen Phase (D(M)) abhängig: B = 2 λ D(M). Je höher die Flussgeschwindigkeit, desto kürzer ist die auf der Säule zugebrachte Zeit und umso geringer wird der Beitrag der Longitudinaldiffusion. C·v beschreibt den Massenübergang zwischen stationärer und mobiler Phase. Dieser Term wird durch die Art der mobilen Phase und die Art und Dicke der stationären Phase beeinflusst. Er ist direkt proportional zur Strömungsgeschwindigkeit.
Sources: de.wikipedia.org
差别集中在三处：第 8 位残基被非天然氨基酸取代，第 34 位换成精氨酸，第 26 位增加一条脂肪酸侧链。前两处改动降低酶解速率，侧链则通过白蛋白结合延长循环时间。综合结果是半衰期从约两分钟延长到约一周。
胰岛素释放需要细胞内环腺苷酸与钙信号升高，同时依赖葡萄糖代谢产生的协同信号。血糖水平较低时协同信号不足，分泌增强有限。这一机制在降糖效果与低血糖风险之间提供了缓冲。
白蛋白结合是主要原因，它减少肾小球滤过并保护分子免受蛋白酶降解。序列修饰带来的酶解抵抗同样不可忽略，二者共同作用。脂肪链的疏水性还会影响组织分布，但其对总半衰期的贡献程度仍在研究之中。
Manufacturers commonly state multi-year stability when the powder is kept dry and frozen. Actual shelf life depends on residual moisture, vial sealing, and storage temperature. A re-test by chromatography is the only way to confirm remaining purity.